PODD Company Profile and Key Details

Insulet Corporation has 70.39 million shares outstanding. The public float is 70.08 million shares, elevated short interest at 3.79% of float. This equals 1.75 million shares. The short ratio is 3.03 days. Institutional investors hold 105.53% of the float. Insiders own 0.71%. Levitz Michael L holds 56.65 thousand shares, Alpuche Charles has 45.58 thousand shares and Hollingshead James has 34.18 thousand shares. Over the past six months, insider transactions show net buying. They sold 1.85 thousand shares across 1 transactions.

Insulet Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $23.60. This means the shares are trading above this model’s fair value.

Short-term trend indicators are bullishly aligned (SMA20 1.06%, SMA50 -6.94%, SMA200 -17.29%). The stock’s 14-day RSI is 46.09 (neutral), while the ATR of 9.77 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -29.13% below its high and over 9.32% above its low. Average 10-day trading volume of 827.25 thousand shares is below the 3-month average of 1.04 million, indicating normal recent market interest.

Insulet Corporation (NASDAQ:PODD) closed at $204.28 USD, gaining $1.78 (0.88%) from the previous close of $202.50. The stock is currently within 5% of its 52-week low $194.61 and $354.88. With a market capitalization of about $14.38 billion, Insulet Corporation is classified as a large-cap and shows higher-than-market volatility (beta ~1.47). Key stats such as the average daily volume over the past year has been around 1.05 million shares, volume is running light vs its 52-week average. Headquartered in Acton, MA, Insulet Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Ashley A. McEvoy, the company employs approximately 5,400 people and listed since May 15, 2007. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.

Insulet Corporation trades at a P/E ratio of 57.3, slightly above the S&P 500 average, with a price-to-sales ratio of 5.23 and a price-to-book ratio of 9.34 trading at moderately above to book value. The P/FCF stands at 37.5, also below market averages.

Insulet Corporation generated EPS of $3.50 over the past year. Five-year average earnings growth is 102.14%. Wall Street analysts project EPS growth of 27.09% annually over the next five years. The latest quarter delivered EPS of $1.24. The next quarter is forecast at $1.20. Next year's EPS is expected at $26.23. Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 25 Buy ratings, 6 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $450.00 to $230.00. The high target offers 123.34% upside. The low target suggests 14.15% downside. The mean target is $366.31. This offers 81.8% upside. Insulet Corporation earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by 9.73%. The prior quarter beat by 27.17%. Over the last six quarters, Apple has recorded several small beats. These include -3.51% in August 08, 2024.

Our AI price prediction model suggests that Insulet Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.97%, with price expected at $181.40 by April 28, 2026, within a range of $176.83 to $185.75 3-Month Outlook: Projected rise of 27.32%, reaching $256.54 by July 13, 2026, with a range of $244.40 to $272.04. 1-Year Outlook: Projected gain of 21.31%, with price at $244.43 by April 14, 2027, within a range of $224.73 to $263.49.

Insulet Corporation (NASDAQ:PODD) shares are flat 0.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Insulet Corporation trading at a premium to the broader market with a P/E of 57.3. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $313.61, suggesting 55.65% upside. Our AI forecast model points to short-term weakness (-9.97% over two weeks), a medium-term rise (27.32% over three months), and a longer-term gain (21.31% over one year), with expected trading ranges indicating moderate volatility.